Technical Analysis for ONCT - Oncternal Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 5.8 10.90% 0.57
ONCT closed up 10.9 percent on Wednesday, August 21, 2019, on 1.5 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical ONCT trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 10.90%

Older signals for ONCT ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on developing a diverse pipeline of product candidates for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody designed to inhibit the ROR1 receptor that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of CLL and MCL, and TK-216, a small-molecule compound that is designed to inhibit ETS-family oncoproteins, which is being evaluated in a Phase 1 clinical trial alone and in combination with vincristine as a treatment for Ewing sarcoma, a rare pediatric cancer. In addition, Oncternal has a CAR-T product candidate that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors.
Biopharmaceutical Cancer Chemical Compounds Organic Compounds Solid Tumors Cancers Drug Development Hematologic Cancers Sarcoma
Is ONCT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 179.2
52 Week Low 3.43
Average Volume 32,419
200-Day Moving Average 7.4444
50-Day Moving Average 5.4136
20-Day Moving Average 4.565
10-Day Moving Average 4.613
Average True Range 0.5297
ADX 26.27
+DI 27.252
-DI 19.5531
Chandelier Exit (Long, 3 ATRs ) 4.2109
Chandelier Exit (Short, 3 ATRs ) 5.0191
Upper Bollinger Band 5.4907
Lower Bollinger Band 3.6393
Percent B (%b) 1.17
BandWidth 40.556407
MACD Line -0.0998
MACD Signal Line -0.3192
MACD Histogram 0.2194
Fundamentals Value
Market Cap 93.14 Million
Num Shares 16.1 Million
EPS -1.71
Price-to-Earnings (P/E) Ratio -3.39
Price-to-Sales 0.00
Price-to-Book 14.80
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.12
Resistance 3 (R3) 6.97 6.39 6.90
Resistance 2 (R2) 6.39 6.05 6.46 6.83
Resistance 1 (R1) 6.09 5.84 6.24 6.24 6.75
Pivot Point 5.51 5.51 5.58 5.58 5.51
Support 1 (S1) 5.21 5.17 5.36 5.36 4.85
Support 2 (S2) 4.63 4.96 4.70 4.77
Support 3 (S3) 4.33 4.63 4.70
Support 4 (S4) 4.48